New Web-Based Genedata Screener Showcases at SLAS2019
The industry’s most widely-used screening data analysis platform extends support for large-molecule screening
February 4, 2019
Washington, DC, USA
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced the release of its new web-based Genedata Screener® 16 at the SLAS 2019 8th Annual Conference and Exhibit. Genedata Screener 16 is built on state-of-the-art web technology, engineered for high performance and complemented by a completely redesigned user interface. Enabling a fully interactive and intuitive review of entire screening campaigns in the browser, the Genedata Screener analysis engine processes millions of data points based on stringent logic and business rules derived from more than 20 years of pharmaceutical process know-how. Genedata Screener 16 allows research organizations to deploy highly efficient and standardized screening analysis to its scientists at zero client footprint. With this latest release, Genedata Screener 16 expands support for scalable and comprehensive characterization of large molecules, including epitope binning. The new web-based Genedata Screener will be demonstrated at the Genedata SLAS Booth #1317 and featured in a SLAS 2019 tutorial session (Walter E. Washington Convention Center).
Integrated, Easily Accessible Platform for Real-time Data Processing
The industry standard in screening data analysis, Genedata Screener is relied on by most of the top biopharma companies and contract research organizations for its integrated end-to-end data capture, analysis and management workflows – from raw data loading and processing to result review and management. Migrating to a modern web application running in popular browsers such as Chrome and Firefox, Genedata Screener 16 minimizes the client footprint and opens the road to real-time, mobile applications. A new real-time dashboard helps scientists to easily define business rules for their campaigns, control automation settings, and monitor screening processes live from anywhere.
As in previous versions of Genedata Screener, the web version offers full scalability, allowing millions of wells to be interactively reviewed in a single session, providing both a birds-eye view of campaigns and instant drill-down to full detail. Its new user interface complies with modern web usage paradigms. Now accessed from the browser, version 16 continues to support the broad range of screening technologies – from endpoint assays, thermal shift experiments, mechanistic and combination assays to high-content, phenotypic, biophysical and electrophysiology screens – ultimately providing the best and broadest enterprise screening analysis on the market.
Scaling-Up Biopharmaceutical Research
As part of the Genedata Biopharma Platform, Genedata Screener works seamlessly with Genedata Biologics to provide analysis workflows in the biopharmaceutical domain. Adding expert assay analysis to the Genedata Biologics workflow backbone, Genedata Screener expands further on biophysical and mechanistic characterization of large molecules. Advancing data analysis from technologies such as Biolayer Interferometry (BLI) and Surface Plasmon Resonance (SPR), it guarantees data traceability and consistent result quality, producing more top-quality candidates in a shorter period of time. Version 16 also provides researchers with an efficient BLI epitope binning analysis workflow for antibody binding site characterization with visualizations enabling a quick and efficient means for quality control.
Intelligent Analysis Automation
The screening lab of the future is automated, and Genedata Screener intends to be the workflow automation platform. With version 16, Genedata Screener supports fully automated screening laboratories with its live monitoring of comprehensive quality control metrics and intuitive visualizations and notifications for operators. Genedata also partners with leading technology providers to streamline the capture of raw data from instruments into Genedata Screener. Current customer collaborations drive further automation in areas such as AI-based analysis and lay the foundation for achieving full process automation.
“We are committed to fully automating data analysis in complex research processes and will continue to invest in software development to help biopharmaceutical research organizations efficiently deliver high-quality data,” said Dr. Othmar Pfannes, CEO of Genedata. “Our strong investment into Genedata Screener shows our continued commitment to supporting our customers by improving the productivity and innovation of biopharmaceutical R&D.”
The following SLAS 2019 tutorials and presentations will be presented by Genedata experts and customers:
“A new enterprise solution for efficient processing of biosensor data (SPR/BLI) for large-molecule screening, antibody characterization, and epitope binning”
Evan Mulligan, Scientific Account Manager, Genedata
Monday, February 4, 2019; 2:00pm-2:45pm; Room 150A
“Genedata Imagence: A new deep learning-based enterprise solution dramatically increases efficiency in HCS image analysis”
Stephan Steigele, Head of Science, Genedata
Tuesday, February 5, 2019; 9:30am-10:15am; Room 151A
“Development of high-throughput data analysis methods to bridge high-throughput APC assay with ion channel research and drug discovery”
Tianbo Li, Scientist, Genentech
Tuesday, February 5, 2019; 12:00pm-12:30pm; Room 147AB
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.